Daniel Heng, MD, MPH, FRCPC, joins us to discuss IMDC

classification for renal cell carcinoma and the treatment of patients withfavorable risk disease. Dr. Heng is a professor of oncology at the Universityof Calgary in Alberta, Canada, and is the leader of the International mRCCDatabase Consortium (IMDC) which consists of data from over 9,200 patients withmRCC treated with targeted therapies from over 38 cancer centers worldwide.